Search research articles
Contact Us
Filters
Showing results (81-90 of 116) with videos related to
Page
of 12
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 2, 2014
Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study
Bernard Escudier, Camillo Porta, Petri Bono, et al.
BMC Medicine
|
October 4, 2019
The VENUSS prognostic model to predict disease recurrence following surgery for non-metastatic papillary renal cell carcinoma: development and evaluation using the ASSURE prospective clinical trial cohort
Tobias Klatte, Kevin M Gallagher, Luca Afferi, et al.
Biology
|
April 11, 2020
The Efficacy of Sunitinib Treatment of Renal Cancer Cells Is Associated with the Protein PHAX In Vitro
Rafia S Al-Lamki, Nicholas J Hudson, John R Bradley, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 10, 2011
A randomized, phase II, biomarker-selected study comparing erlotinib to erlotinib intercalated with chemotherapy in first-line therapy for advanced non-small-cell lung cancer
Fred R Hirsch, Fairooz Kabbinavar, Tim Eisen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 26, 2006
Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma
Mark J Ratain, Tim Eisen, Walter M Stadler, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 11, 2007
Tumor necrosis factor alpha as a new target for renal cell carcinoma: two sequential phase II trials of infliximab at standard and high dose
Michelle L Harrison, Eva Obermueller, Nick R Maisey, et al.
European Urology
|
May 23, 2018
Adjuvant Vascular Endothelial Growth Factor-targeted Therapy in Renal Cell Carcinoma: A Systematic Review and Pooled Analysis
Maxine Sun, Lorenzo Marconi, Tim Eisen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 20, 2009
Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial
Bernard Escudier, Tim Eisen, Walter M Stadler, et al.
The New England Journal of Medicine
|
January 12, 2007
Sorafenib in advanced clear-cell renal-cell carcinoma
Bernard Escudier, Tim Eisen, Walter M Stadler, et al.
The Lancet. Oncology
|
October 11, 2016
IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial
Brian I Rini, Arnulf Stenzl, Romauld Zdrojowy, et al.
Page
of 12
Search research articles
Search
Showing results (81-90 of 116) with videos related to
Sort By:
Page
of 12
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 2, 2014
Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study
Bernard Escudier, Camillo Porta, Petri Bono, et al.
BMC Medicine
|
October 4, 2019
The VENUSS prognostic model to predict disease recurrence following surgery for non-metastatic papillary renal cell carcinoma: development and evaluation using the ASSURE prospective clinical trial cohort
Tobias Klatte, Kevin M Gallagher, Luca Afferi, et al.
Biology
|
April 11, 2020
The Efficacy of Sunitinib Treatment of Renal Cancer Cells Is Associated with the Protein PHAX In Vitro
Rafia S Al-Lamki, Nicholas J Hudson, John R Bradley, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 10, 2011
A randomized, phase II, biomarker-selected study comparing erlotinib to erlotinib intercalated with chemotherapy in first-line therapy for advanced non-small-cell lung cancer
Fred R Hirsch, Fairooz Kabbinavar, Tim Eisen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 26, 2006
Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma
Mark J Ratain, Tim Eisen, Walter M Stadler, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 11, 2007
Tumor necrosis factor alpha as a new target for renal cell carcinoma: two sequential phase II trials of infliximab at standard and high dose
Michelle L Harrison, Eva Obermueller, Nick R Maisey, et al.
European Urology
|
May 23, 2018
Adjuvant Vascular Endothelial Growth Factor-targeted Therapy in Renal Cell Carcinoma: A Systematic Review and Pooled Analysis
Maxine Sun, Lorenzo Marconi, Tim Eisen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 20, 2009
Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial
Bernard Escudier, Tim Eisen, Walter M Stadler, et al.
The New England Journal of Medicine
|
January 12, 2007
Sorafenib in advanced clear-cell renal-cell carcinoma
Bernard Escudier, Tim Eisen, Walter M Stadler, et al.
The Lancet. Oncology
|
October 11, 2016
IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial
Brian I Rini, Arnulf Stenzl, Romauld Zdrojowy, et al.
Page
of 12